Tuesday April 25, 9:02 am Eastern Time
Company Press Release
GenStar Therapeutics Announces Issuance of Patent for Sensitizing Tumors to Radiation Using Gene Therapy
SAN DIEGO--(BW HealthWire)--April 25, 2000--GenStar Therapeutics (AMEX: GNT - news), a biotechnology company developing products for the treatment of hemophilia A and prostate cancer, announced today the issuance of U.S. Patent No. 6,051,218 entitled, ``Tumor Radiosensitization Using Gene Therapy.'' This University of California patent covers a method of inhibiting the growth of a cancerous tumor by delivering the cytokine gene interleukin-3 to sensitize tumors to standard radiation therapy. GenStar exclusively licensed the patent for use in developing a novel treatment for prostate and other cancers. In addition, the patent has been exclusively licensed to The Immune Response Corporation (NASDAQ: IMNR - news), in Carlsbad, California, for the use in the prevention and treatment of colon cancer, brain tumors and melanoma.
``The receipt of this patent enhances GenStar's unique approach to treating prostate cancer via multiple modes of action that includes sensitizing tumors to the effects of standard radiation by gene therapy,'' said Robert E. Sobol, M.D., President and CEO of GenStar Therapeutics.
Company Press Release
GenStar Therapeutics Announces Issuance of Patent for Sensitizing Tumors to Radiation Using Gene Therapy
SAN DIEGO--(BW HealthWire)--April 25, 2000--GenStar Therapeutics (AMEX: GNT - news), a biotechnology company developing products for the treatment of hemophilia A and prostate cancer, announced today the issuance of U.S. Patent No. 6,051,218 entitled, ``Tumor Radiosensitization Using Gene Therapy.'' This University of California patent covers a method of inhibiting the growth of a cancerous tumor by delivering the cytokine gene interleukin-3 to sensitize tumors to standard radiation therapy. GenStar exclusively licensed the patent for use in developing a novel treatment for prostate and other cancers. In addition, the patent has been exclusively licensed to The Immune Response Corporation (NASDAQ: IMNR - news), in Carlsbad, California, for the use in the prevention and treatment of colon cancer, brain tumors and melanoma.
``The receipt of this patent enhances GenStar's unique approach to treating prostate cancer via multiple modes of action that includes sensitizing tumors to the effects of standard radiation by gene therapy,'' said Robert E. Sobol, M.D., President and CEO of GenStar Therapeutics.
